Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

  title={Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia},
  author={Denis Yu. Logunov and Inna V. Dolzhikova and Olga V. Zubkova and Amir I. Tukhvatulin and Dmitry V. Shcheblyakov and Alina S Dzharullaeva and Daria M. Grousova and Alina S Erokhova and Anna V. Kovyrshina and Andrei G. Botikov and Fatima M. Izhaeva and Olga Popova and Tatiana A Ozharovskaya and Ilias B. Esmagambetov and Irina A. Favorskaya and D. I. Zrelkin and Daria V. Voronina and Dmitry N. Shcherbinin and A. S. Semikhin and Yana V. Simakova and Elizaveta A. Tokarskaya and Nadezhda L. Lubenets and Daria A. Egorova and Maksim Shmarov and Natalia A Nikitenko and Lola Morozova and Elena A. Smolyarchuk and Evgeny Vladimirovich Kryukov and V. F. Babira and S. V. Borisevich and Boris S. Naroditsky and Alexander L Gintsburg},
  journal={Lancet (London, England)},
  pages={887 - 897}

Figures and Tables from this paper

Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial

Heterologous boosting with ZF001 following primary vaccination of Convidecia is safe and more immunogenic than a single dose ofconvidecia, and results support flexibility in cooperating viral vectored vaccines and recombinant protein vaccine.

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials

The safety and immunogenicity data from phase 1 and 2 trials for ZF2001 support the use of 25 g vaccine dose with three-dose schedule to an ongoing phase 3 large-scale evaluation for safety and efficacy.

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

It is demonstrated that a booster dose of ChAdOx1 nCoV-19 is safe and better tolerated than priming doses, and anti-spike neutralizing antibody titers, as well as Fc-mediated functional antibody responses, including antibody-dependent neutrophil/monocyte phagocytosis, complement activation and natural killer cell activation, are substantially enhanced by a booster doses of vaccine.

Immunogenicity and Safety of a Three-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-blind, Placebo-controlled Phase 2 Trial

Two doses of this vaccine induced robust immune response and had good safety profile and Seroconversion percentages were 94% or more after two doses, which were generally similar after three doses.

Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report

Interim findings of a controlled, randomised, double-blind trial on the immunogenicity and safety of BBV152, 3{ micro} and 6{micro} with Algel-IMDG suggest that the safety profile of this vaccine is noticeably lower than the rates for other SARS-CoV-2 vaccine platform candidates.



Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia

The data indicate that the vaccine is safe and induces strong humoral and cellular immune response in up to 100 % of healthy adult volunteers, and provide a rationale for testing efficacy in Phase III trials.

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine.

A heterologous virus-vectored vaccine for prevention of Middle East respiratory syndrome induces long protective immune response against MERS-CoV

The present research showed that vaccination of animals with BVRS-GamVac-Combi induced robust humoral immune response, which persisted at least 18 months after immunization, and protected 100 % of animals from lethal infection for at least 7 months after Immunization.

Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2 Vaccine Design

The structure-based immunoinformatic analysis for the SARS-CoV-2 S protein in this study may improve vaccine design, diagnosis, and immunotherapy against the pandemic of COVID-19.

Virus-Vectored Ebola Vaccines

This review focuses on virus-vectored Ebola vaccines that have demonstrated the greatest efficacy in preclinical trials and are currently under different phases of clinical trial, and the key vaccine parameters necessary for inducing long-term protective immunity against EVD.

Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens

This review focuses on the application of adenoviral-vectored vaccines in mucosal immunization strategies against mucosal pathogens including Mycobacterium tuberculosis, flu virus, and human immunodeficiency virus.

Adenoviruses as vaccine vectors